T-cell receptor repertoires as potential diagnostic markers for patients with COVID-19Controlled Trial Published on 2021-10-222023-06-15 Journal: International Journal of Infectious Diseases [Category] MERS, [키워드] Adaptive immunity BWNW, Bloodworks Northwest CDR3, complementarity-determining region 3 Coronavirus disease 2019 COVID-19, Coronavirus disease 2019 DLS, Discovery Life Science HC, Healthy control HUniv12Oct, Hospital Univesitario 12 de Octubre SARS-CoV-2 SARS-CoV-2, Severe acute respiratory syndrome coronavirus 2 T-cell receptor TCR, T-cell receptor TCRβ, T-cell receptor beta chain TRBJ, TCR beta chain joining gene TRBV, TCR beta chain variable gene [DOI] 10.1016/j.ijid.2021.10.033 PMC 바로가기 [Article Type] Controlled Trial
Rapid, robust, and sustainable antibody responses to mRNA COVID-19 vaccine in convalescent COVID-19 individuals회복기 COVID-19 개인에서 mRNA COVID-19 백신에 대한 신속하고 강력하며 지속 가능한 항체 반응Research Article Published on 2021-10-222022-09-12 Journal: JCI Insight [Category] MERS, SARS, 진단, [키워드] 350 patients Adaptive immunity antibody antibody levels Antibody Response BNT162b2 conditions convalescent COVID-19 COVID-19 patients COVID-19 vaccine diagnosed diagnosed with COVID-19 Efficacy elicit evaluate Follow-up Hospitalized immunology individual investigated Longitudinal studies longitudinal study measure mRNA mRNA vaccine neutralizing antibody quantity Rapid rapid increase reached robust SARS-CoV-2 SARS-CoV-2 antibody second dose significantly SNAb specimen the SARS-CoV-2 These data total antibody Vaccine vaccine dose vaccine efficacy [DOI] 10.1172/jci.insight.151477 PMC 바로가기 [Article Type] Research Article
Attenuated activation of pulmonary immune cells in mRNA-1273–vaccinated hamsters after SARS-CoV-2 infectionResearch Article Published on 2021-10-152023-06-16 Journal: The Journal of Clinical Investigation [Category] MERS, SARS, [키워드] Adaptive immunity bioinformatics Cellular immune response immunology Vaccines [DOI] 10.1172/JCI148036 PMC 바로가기 [Article Type] Research Article
SARS-CoV-2 immunity and functional recovery of COVID-19 patients 1-year after infectionSARS-CoV-2 감염 1년 후 COVID-19 환자의 면역 및 기능 회복Clinical Trial Published on 2021-10-132022-09-10 Journal: Signal Transduction and Targeted Therapy [Category] MERS, SARS, 변종, 임상, 진단, 치료기술, 치료제, [키워드] 95% CI Adaptive immunity analyzed Anti-RBD IgG anti-receptor-binding domain antibody B.1.1.7 B.1.351 B.1.351 variant B.1.351 variants chemiluminescence chemiluminescence immunoassay Chest CT China consequence COVID-19 COVID-19 patient COVID-19-related symptoms detectable Diagnosis discharge estimate functional General population highlight immune immune protection Immunity implication Infection Infectious diseases life long-lasting neutralization non-severe patient Outcomes research participant Patient Predictive preventive measure preventive measures prospective cohort Pulmonary function Quality of life RBD Re-infection recovered COVID-19 patient reduced remained reported risk SARS-CoV-2 immunity SARS-COV-2 infection Seroprevalence Severe patient severe patients significantly Survivors symptomatic Total variant WT SARS-CoV-2 [DOI] 10.1038/s41392-021-00777-z PMC 바로가기 [Article Type] Clinical Trial
SARS–CoV–2 Spike Impairs DNA Damage Repair and Inhibits V(D)J Recombination In VitroSARS – COV – 2 스파이크는 DNA 손상 복구를 손상시키고 V (D) J J 재조합을 억제합니다.Article Published on 2021-10-132022-09-01 Journal: Viruses [Category] MERS, SARS, 유전자 메커니즘, 진단, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus adaptive Adaptive immunity affecting BRCA1 cell line clinical Clinical outcome clinical outcomes Clinical studies coronavirus coronavirus disease Coronavirus disease 2019 damage DNA DNA damage DNA damage repair DNA repair effective full-length immune immune responses Immunity impede in vitro indicated Infection influence inhibit mechanism nucleus pandemic Patient patients potential molecular Protein public health Recombination recruitment repair required respiratory SARS–CoV–2 severe acute respiratory syndrome Coronavirus severe acute respiratory syndrome coronavirus 2 Side effect significantly spike Spike protein spike-based vaccines the spike protein V(D)J recombination Vaccine [DOI] 10.3390/v13102056 PMC 바로가기 [Article Type] Article
Comparison of antibody and T cell responses elicited by BBIBP-CorV (Sinopharm) and BNT162b2 (Pfizer-BioNTech) vaccines against SARS-CoV-2 in healthy adult humans건강한 성인에서 SARS-CoV-2에 대한 BBIBP-CorV(Sinopharm) 및 BNT162b2(Pfizer-BioNTech) 백신에 의해 유도된 항체 및 T 세포 반응의 비교Original Article Published on 2021-10-112022-09-11 Journal: GeroScience [Category] MERS, SARS, 치료법, [키워드] adaptive Adaptive immunity Analysis anti-SARS-CoV-2 anti-SARS-CoV-2 antibodies Anti-spike antibody BBIBP-CorV BNT162b2 cell-mediated immune response Cell-mediated immune responses Convalescent patients cumulative domain effective elicit elicited epitope Epitopes evaluate healthy healthy individuals Human humoral IFNγ ELISpot assay IFNγ-producing T cells IFNγ IgA antibodies IgA antibody IgG immune response immune responses Immunity immunologically in healthy individuals inactivated injected investigated Live virus membrane mRNA mRNA vaccine mRNA-based much lower nucleocapsid participant pattern Pfizer-BioNTech Protein Proteins Quantitative RBD S protein epitopes SARS-CoV-2 SARS-CoV-2 virus Sinopharm supplementary material T cell T cell response target the S protein These data vaccination Vaccine virus Volunteer [DOI] 10.1007/s11357-021-00471-6 PMC 바로가기 [Article Type] Original Article
Exposure to Diverse Plasmodium falciparum Genotypes Shapes the Risk of Symptomatic Malaria in Incident and Persistent Infections: A Longitudinal Molecular Epidemiologic Study in Kenya다양한 플라스모디움 팔시파룸 유전자형에 대한 노출이 발생 및 지속 감염에서 증상성 말라리아의 위험을 형성한다: 케냐에서의 종단적 분자 역학 연구Article Published on 2021-10-012024-08-08 Journal: Clinical infectious diseases : an official publication of the Infectious [Category] 말라리아, [키워드] Adaptive immunity Asymptomatic falciparum malaria [DOI] 10.1093/cid/ciab357 PMC 바로가기
Current scenario of COVID-19 vaccinations and immune response along with antibody titer in vaccinated inhabitants of different countries다른 국가의 예방 접종을받은 주민의 항체 역가와 함께 COVID-19 예방 접종 및 면역 반응의 현재 시나리오Review Published on 2021-10-012022-09-11 Journal: International immunopharmacology [Category] SARS, 변종, [키워드] Adaptive immunity addition addressed Antibody titer approach cellular Cellular and humoral responses cellular immunity Clinical management clinical trial Combination country COVID-19 COVID-19 pandemic COVID-19 vaccination Critical current generate Humoral response immune immune response immune responses Immunity inactivated induce Infection long-lasting neutralization Neutralizing antibodies nucleic acid overcome pathogenicity peptide phase 4 Population proportion response rising Safe Safety assessment SARS-CoV-2 SARS-CoV-2 variants Spread Trial vaccination Vaccine vaccine candidates Vaccine development Vaccine-induced immunity Vaccines variant variants variants of SARS-CoV-2 virus virus-neutralizing antibodies virus-neutralizing antibody [DOI] 10.1016/j.intimp.2021.108050 PMC 바로가기 [Article Type] Review
Normal T and B Cell Responses Against SARS-CoV-2 in a Family With a Non-Functional Vitamin D Receptor: A Case ReportImmunology Published on 2021-09-302022-11-01 Journal: Frontiers in Immunology [Category] COVID-19, SARS, [키워드] acute respiratory syndrome adaptive Adaptive immune response Adaptive immunity Against coronavirus coronavirus disease Course COVID-19 COVID-19 severity decrease disease severity family General population HVDRR immune response Immunity impacted inverse correlation measure mutated normal observation pandemic plasma question recent reduce report reported response SARS-CoV-2 SARS-COV-2 infection Signaling Spread susceptibility transferred Vitamin D Vitamin D receptor [DOI] 10.3389/fimmu.2021.758154 PMC 바로가기 [Article Type] Immunology
Genetic and structural basis for SARS-CoV-2 variant neutralization by a two-antibody cocktailArticle Published on 2021-09-302023-06-15 Journal: Nature Microbiology [Category] MERS, SARS, [키워드] Adaptive immunity antibodies coronavirus COVID-19 Human monoclonal SARS-CoV SARS-CoV-2 [DOI] 10.1038/s41564-021-00972-2 PMC 바로가기 [Article Type] Article